RNA Targeted Small Molecules: Finally Drug the “Undruggable” RNA
At a time when the previously untapped drug discovery opportunity promised within RNA opens up, the 2nd RNA- Targeted Drug Discovery Summit returns to reunite the leading minds from large pharma, innovative biotech and KOLs of academia to overcome unique discovery and development challenges associated with novel RNA targeted small molecule therapeutics and achieve their seemingly limitless potential.
Our mission for this meeting is simple: to provide you with a comprehensive understanding on how to translate the first generation of RNA targeted small molecules into the clinic, delve into the exciting field of epitranscriptomics and stimulate discussion on how to successfully target RNA via RNA- modifying enzymes and interfering with RNA-protein interactions.
Take a look at the comprehensive agenda and full speaker line up here.
Just some of our expert speakers already confirmed include:
- Kevin Weeks, Founder of Ribometrix; Professor of Chemistry, University of North Carolina
- Frank Slack, Co-Founder of Twentyeight-Seven Therapeutics; Professor, BIDMC
- Kathryn McCabe, Director of Business Development, Eli Lilly
- Martin Pettersson, Research Fellow, Pfizer
- Christopher Barbieri, Senior Investigator, Bristol-Myers Squibb
- Jennifer Petter, Founder & CSO, Arrakis Therapeutics
- Yochi Slonim, Co-founder & CEO, Anima Biotech
- Gerhard Mueller, CSO, Gotham Therapeutics
- Christopher R. Trotta, VP, Biology, PTC Therapeutics
With numerous approaches emerging that demonstrate genuinely viable efficacy in targeting RNA, join the discussion alongside 100+ highly focused peers and leaders for exclusive insights that will inspire you to successfully re-define the undruggable nature of RNA once and for all.
Click here to see the full program and speaker line-up.
We hope you can join us. Pharma Journalist readers receive an exclusive 10% discount to attend the forum. Simply quote VIP Code PJPR10 at checkout to receive your discount.
Sign yourself up here.
We hope you’ll be able to join us.
The RNA-Targeted Drug Discovery Team